Annexon Bets on Vision Preservation to Redefine Geographic Atrophy Treatment

BRISBANE, Calif. – February 17, 2026 – As the race to treat a leading cause of blindness intensifies, Annexon Biosciences is making a strategic push to highlight a novel therapeutic approach that prioritizes preserving sight over merely slowing disease progression. The company announced today it will host a key opinion leader (KOL) event in March to showcase Vonaprument, its investigational therapy for geographic atrophy (GA), an advanced and debilitating form of dry age-related macular degeneration (AMD).

The event, scheduled for March 18, comes as the company advances its pivotal Phase 3 ARCHER II trial, with highly anticipated topline data expected in the second half of 2026. For the nearly one million Americans and five million people worldwide living with GA, the outcome could signal a new frontier in treatment, shifting the focus from managing retinal damage to protecting functional vision.

A New Paradigm for a Devastating Disease

Geographic atrophy is a slow, relentless theft of sight. It causes irreversible loss of central vision by destroying photoreceptor cells in the retina, creating blind spots that expand over time and make everyday activities like reading, driving, and recognizing faces impossible. For decades, patients had no therapeutic options.

That changed in 2023 with the FDA approval of the first-ever treatments for GA: Apellis Pharmaceuticals’ Syfovre and Astellas Pharma’s Izervay. Both drugs work by inhibiting parts of the body's complement system, an inflammatory pathway implicated in the disease. While representing a landmark achievement, these therapies have limitations. Clinical data shows they slow the growth rate of retinal lesions by approximately 15-30% but do not stop the disease, reverse damage, or improve vision. Furthermore, safety concerns, including a risk of inflammation and an increased incidence of choroidal neovascularization (wet AMD), have tempered enthusiasm and contributed to a lack of approval in Europe.

This landscape leaves a significant unmet need for therapies that can offer more than just pumping the brakes on lesion growth. The ultimate goal for patients is not just a smaller area of damage on a retinal scan, but the preservation of the vision they still have.

Targeting the Source: The C1q Inhibition Strategy

Annexon's Vonaprument enters the field with a fundamentally different strategy. Instead of targeting the complement components C3 or C5, which are involved in all three complement pathways, Vonaprument is an antigen-binding fragment (Fab) designed to selectively inhibit C1q. C1q is the initiating molecule of the classical complement pathway, which research suggests is a key driver of synapse loss and neurodegeneration in the retina.

By blocking the pathway at its source, Annexon posits that Vonaprument can provide a neuroprotective effect, shielding precious photoreceptor cells and their connections from inflammatory damage. The company argues this targeted approach is more precise, designed to stop the specific classical complement-driven neuroinflammation that destroys retinal function while leaving the other beneficial immune functions of the lectin and alternative pathways intact. It’s a strategy akin to disabling a single faulty circuit rather than shutting down the entire power grid, potentially offering a better safety and efficacy profile.

This differentiated mechanism is the foundation for Vonaprument’s potential to be the first targeted vision-preserving therapy for GA, a claim that has earned it both Fast Track designation from the U.S. FDA and Priority Medicine (PRIME) designation from the European Medicines Agency.

High Stakes and High Hopes: The Road to Phase 3

The scientific rationale behind Vonaprument was put to the test in the Phase 2 ARCHER study, which yielded a complex but promising set of results. The drug did not meet its primary endpoint of significantly slowing the growth of GA lesions compared to a sham procedure. However, it succeeded on a critical secondary endpoint that has now become the company's central focus: protecting patients from significant vision loss.

In that trial, patients receiving monthly injections of Vonaprument experienced a statistically significant 72% reduction in their risk of losing 15 or more letters of vision on a standard eye chart over 12 months—a clinically meaningful measure equivalent to three lines of sight. This powerful signal of functional benefit, even in the absence of slowing lesion growth, prompted Annexon to pivot its clinical strategy.

Consequently, the ongoing global Phase 3 ARCHER II trial, which has enrolled over 630 patients, now uses the prevention of ≥15-letter vision loss as its primary endpoint. This is a well-established functional endpoint that has served as the basis for numerous ophthalmology drug approvals, aligning the trial's goal directly with the most important outcome for patients.

Building Momentum in a Competitive Field

With pivotal data on the horizon, Annexon's upcoming KOL event is a clear effort to educate the medical and investment communities on its unique value proposition. The event will feature presentations from two of the field’s most respected experts: Dr. Eleanora Lad of Duke University Medical Center and Dr. Charles Wykoff of Retina Consultants of Texas, both of whom are deeply involved in AMD research and clinical trials.

Their participation lends significant credibility as Annexon navigates an increasingly competitive landscape. While Syfovre and Izervay are on the market, other companies like Belite Bio and Ocugen are advancing their own late-stage candidates with different mechanisms of action. The global market for GA therapies is projected to reach an astounding $50 billion by 2032, making the stakes incredibly high.

For Annexon, the road ahead is one of high risk and high reward. Financial analysts have set optimistic price targets for the company's stock, buoyed by the potential of its C1q platform. However, the company remains unprofitable, burning through capital to fund its ambitious clinical programs. Success for Vonaprument in the ARCHER II trial could validate its entire platform and transform the standard of care for millions. Failure would be a significant setback. As the second half of 2026 approaches, all eyes in the ophthalmology world will be on Annexon, waiting to see if its bold bet on preserving vision will pay off.